Knights Of Columbus Asset Advisors LLC Fate Therapeutics Inc Transaction History

Knights Of Columbus Asset Advisors LLC

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 31, 2024	BUY	$1.65 - $3.94 $26,551 - $63,402	16,092 Added 100.0%	32,184 $120,000
Q2 2023 Jul 31, 2023	SELL	$4.76 - $6.59 $60,847 - $84,239	-12,783 Reduced 44.27%	16,092 $76,000
Q4 2022 Jan 31, 2023	SELL	$9.86 - $23.83 $2,987 - $7,220	-303 Reduced 1.04%	28,875 $291,000
Q3 2022 Nov 10, 2022	BUY	$21.04 - $36.06 $74,334 - $127,399	3,533 Added 13.78%	29,178 $654,000
Q2 2022 Aug 12, 2022	BUY	$17.78 - $42.39 $1,778 - $4,239	100 Added 0.39%	25,645 $635,000
Q1 2022 May 16, 2022	BUY	$29.67 - $60.28 $8,544 - $17,360	288 Added 1.14%	25,545 $990,000
Q4 2021 Feb 11, 2022	BUY	$47.84 - $64.34 $23,872 - $32,105	499 Added 2.02%	25,257 $1.48 Million
Q3 2021 Nov 10, 2021	BUY	$59.27 - $95.73 $1,185 - $1,914	20 Added 0.08%	24,758 $1.47 Million
Q2 2021 Aug 12, 2021	BUY	$67.25 - $92.52 $192,335 - $264,607	2,860 Added 13.07%	24,738 $2.15 Million
Q1 2021 May 17, 2021	SELL	$72.16 - $117.4 $20,782 - $33,811	-288 Reduced 1.3%	21,878 $1.8 Million
Q4 2020 Feb 16, 2021	SELL	$38.09 - $100.95 $532,764 - $1.41 Million	-13,987 Reduced 38.69%	22,166 $2.02 Million
Q3 2020 Nov 13, 2020	SELL	$30.41 - $40.5 $159,774 - $212,787	-5,254 Reduced 12.69%	36,153 $1.45 Million
Q2 2020 Aug 14, 2020	BUY	$20.21 - $35.23 $36,539 - $63,695	1,808 Added 4.57%	41,407 $1.42 Million
Q1 2020 May 15, 2020	SELL	$17.28 - $31.88 $443,871 - $818,901	-25,687 Reduced 39.35%	39,599 $879,000
Q4 2019 Feb 14, 2020	BUY	$13.39 - $20.73 $874,179 - $1.35 Million	65,286 New	65,286 $1.28 Million

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $220M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Knights Of Columbus Asset Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Knights Of Columbus Asset Advisors LLC with notifications on news.